Intellectual Property India Publishes Patent Application for 'Synthesis And Characterization And Antifungal Activity Evaluation Of 5 Acetyl-4-(3'ethoxyp,4'hydrooxyhenyl)-6-Methyl-3,4-Dihydropyrimidine-2(1h)-One' Filed by S. V. Sai Kumar; Dr. Kiran Mandda; Dr. Kamepalli Ramanjaneyulu; Pasumarthi Venkateswara Rao; Adi Dileep; Katta Tarun; and Shri Vishnu College Of Phamacy

MUMBAI, India, March 13 -- Intellectual Property India has published a patent application (202641003484 A) filed by S. V. Sai Kumar; Dr. Kiran Mandda; Dr. Kamepalli Ramanjaneyulu; Pasumarthi Venkateswara Rao; Adi Dileep; Katta Tarun; and Shri Vishnu College Of Phamacy, Bhimavaram, Andhra Pradesh, on Jan. 13, for 'synthesis and characterization and antifungal activity evaluation of 5 acetyl-4-(3'ethoxyp,4'hydrooxyhenyl)-6-methyl-3,4-dihydropyrimidine-2(1h)-one.'

Inventor(s) include S. V. Sai Kumar; Dr. Kiran Mandda; Dr. Kamepalli Ramanjaneyulu; Pasumarthi Venkateswara Rao; Adi Dileep; and Katta Tarun.

The application for the patent was published on March 13, under issue no. 11/2026.

According to the abstract released by the Intellectual Property India: "The present study focuses on the formulation and evaluation of extended-release tablets of Metoprolol Succinate, a ~!-adrenergic receptor antagonist widely prescribed for hypertension, angina pectoris, and heart failure. The objective was to develop a controlled-release dosag~ form that maintains therapeutic plasma concentrations for an extended period, thereby enhancing patient compliance and minimizing dosing frequency. Various formulations were preRared using both synthetic (HPMC KlOOM, Sodium CMC) and natural polymers (Guar gum, Xanthan gm:_n,CSodium algin.ate) !hrough non-aqut!QUS wet granulatinr,L Th~ _ prepared tablets were evaluated for pre-compression and post-compressi_on parameters, in vitro drug "release kinetics, and stability studies. Amon'g the formulations, FlO (containing 30% HPMC KlOOM and 10% Sodium alginate) exhibited sustained zero-order release up to 12 hours with stable physicochemical characteristics. The optimized formulation demonstrated diffusion-controlled, non-Fickian drug release behaviour and was found to be stable as per ICH guidelines. This study successfully establishes a cost-effective extended-release oral matrix system for Metoprolol Succinate with potential to improve therapeutic efficacy and patient adherence."

Disclaimer: Curated by HT Syndication.